NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Active, not recruiting · NCT04005339 · Registry updated 2026-01-26Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, digestive system disorder, digestive system neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2026-01-26 | NCT04005339 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Georgetown University | 73 |
| Ipsen | 59 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | New York | United States | 7 |
| Indiana University Health Melvin and Bren Simon Cancer Center | Indianapolis | United States | 5 |
| Lombardi Comprehensive Cancer Center, Georgetown University | Washington D.C. | United States | 7 |
| Washington University School of Medicine- Siteman Cancer Center | St Louis | United States | 1 |